BACKGROUND: A standardized protocol for measuring mucociliary (MCC) and cough clearance (CC) was developed and tested at the University of North Carolina at Chapel Hill, NC (UNC), Johns Hopkins University (JHU), and the University of Pittsburgh (Pitt). METHODS: A total of 50 healthy nonsmoking adults with normal lung function were studied at the three sites: 30 [21 males/9 females (21M/9F)] at UNC, 10 (6M/4F) at JHU, and 10 (4M/6F) at Pitt. Subjects inhaled an aerosol of (99m)technetium sulfur colloid in 0.9% saline (mass median aerodynamic diameter=5.4 μm) under controlled breathing conditions (500 mL/sec, 30 breaths/min) by following a metronome and flow signal from a commercial dosimeter. Following inhalation, subjects sat in front of a gamma camera as sequential lung images were acquired for 60 min. Subjects then coughed 60 times, and images were acquired after each set of 20 coughs, i.e., at 70, 80, and 90 min. Subjects returned to the laboratory approximately 24 hr later for a final image of residual lung activity. Initial aerosol distribution was measured as a central/peripheral (C/P) ratio of activity. MCC/CC was expressed as the area under the retention versus time curve over 90 min (AUC90). RESULTS: A multivariate analysis of clearance versus time with site and C/P as covariates showed no significant site-specific differences. Interestingly, MCC/CC was greater in females (n=19) versus males (n=31), with AUC90=0.84 ± 0.11 and 0.90±0.07, respectively (p=0.03), for the combined data set from all sites (not significant for any given site). There were no gender differences for either C/P ratio or 24-hr clearance. CONCLUSIONS: This standardized protocol may prove beneficial in multicenter trials for testing new therapies that are designed to improve MCC/CC.
BACKGROUND: A standardized protocol for measuring mucociliary (MCC) and cough clearance (CC) was developed and tested at the University of North Carolina at Chapel Hill, NC (UNC), Johns Hopkins University (JHU), and the University of Pittsburgh (Pitt). METHODS: A total of 50 healthy nonsmoking adults with normal lung function were studied at the three sites: 30 [21 males/9 females (21M/9F)] at UNC, 10 (6M/4F) at JHU, and 10 (4M/6F) at Pitt. Subjects inhaled an aerosol of (99m)technetium sulfur colloid in 0.9% saline (mass median aerodynamic diameter=5.4 μm) under controlled breathing conditions (500 mL/sec, 30 breaths/min) by following a metronome and flow signal from a commercial dosimeter. Following inhalation, subjects sat in front of a gamma camera as sequential lung images were acquired for 60 min. Subjects then coughed 60 times, and images were acquired after each set of 20 coughs, i.e., at 70, 80, and 90 min. Subjects returned to the laboratory approximately 24 hr later for a final image of residual lung activity. Initial aerosol distribution was measured as a central/peripheral (C/P) ratio of activity. MCC/CC was expressed as the area under the retention versus time curve over 90 min (AUC90). RESULTS: A multivariate analysis of clearance versus time with site and C/P as covariates showed no significant site-specific differences. Interestingly, MCC/CC was greater in females (n=19) versus males (n=31), with AUC90=0.84 ± 0.11 and 0.90±0.07, respectively (p=0.03), for the combined data set from all sites (not significant for any given site). There were no gender differences for either C/P ratio or 24-hr clearance. CONCLUSIONS: This standardized protocol may prove beneficial in multicenter trials for testing new therapies that are designed to improve MCC/CC.
Authors: Beth L Laube; Kathryn A Carson; Gail Sharpless; Laura M Paulin; Nadia N Hansel Journal: J Aerosol Med Pulm Drug Deliv Date: 2019-04-08 Impact factor: 2.849
Authors: Timothy E Corcoran; Alex S Huber; Michael M Myerburg; Daniel J Weiner; Landon W Locke; Ryan T Lacy; Lawrence Weber; Michael R Czachowski; Darragh J Johnston; Ashok Muthukrishnan; Alison T Lennox; Joseph M Pilewski Journal: J Aerosol Med Pulm Drug Deliv Date: 2019-04-10 Impact factor: 2.849
Authors: Wayne H Anderson; Raymond D Coakley; Brian Button; Ashley G Henderson; Kirby L Zeman; Neil E Alexis; David B Peden; Eduardo R Lazarowski; C William Davis; Summer Bailey; Fred Fuller; Martha Almond; Bahjat Qaqish; Elena Bordonali; Michael Rubinstein; William D Bennett; Mehmet Kesimer; Richard C Boucher Journal: Am J Respir Crit Care Med Date: 2015-07-15 Impact factor: 21.405
Authors: Scott H Donaldson; Beth L Laube; Timothy E Corcoran; Pradeep Bhambhvani; Kirby Zeman; Agathe Ceppe; Pamela L Zeitlin; Peter J Mogayzel; Michael Boyle; Landon W Locke; Michael M Myerburg; Joseph M Pilewski; Brian Flanagan; Steven M Rowe; William D Bennett Journal: JCI Insight Date: 2018-12-20
Authors: Timothy E Corcoran; Joseph E Godovchik; Karl H Donn; David R Busick; Jennifer Goralski; Landon W Locke; Matthew R Markovetz; Michael M Myerburg; Ashok Muthukrishnan; Lawrence Weber; Ryan T Lacy; Joseph M Pilewski Journal: Pediatr Pulmonol Date: 2017-07-24
Authors: William D Bennett; Neil E Alexis; Martha Almond; Margaret Herbst; Kirby L Zeman; David B Peden Journal: J Aerosol Med Pulm Drug Deliv Date: 2014-12 Impact factor: 2.849
Authors: William D Bennett; Miao Xie; Kirby Zeman; Harry Hurd; Scott Donaldson Journal: J Aerosol Med Pulm Drug Deliv Date: 2014-11-13 Impact factor: 2.849
Authors: W D Bennett; J Wu; F Fuller; J R Balcazar; K L Zeman; H Duckworth; K H Donn; T G O'Riordan; R C Boucher; S H Donaldson Journal: J Appl Physiol (1985) Date: 2015-04-24
Authors: Aaron T Trimble; A Whitney Brown; Beth L Laube; Noah Lechtzin; Kirby L Zeman; Jihong Wu; Agathe Ceppe; David Waltz; William D Bennett; Scott H Donaldson Journal: J Cyst Fibros Date: 2018-01-20 Impact factor: 5.482